RSS-Feed abonnieren

DOI: 10.1055/s-0043-1772820
Profile of Neuromuscular Disorders: Neurology Clinic, Tripoli Children Hospital
Funding and Sponsorship None.

Abstract
Objective Neuromuscular disorders (NMDs) are any diseases affecting the lower motor neuron (anterior horn cell, peripheral nerve, and neuromuscular junction) or muscle, all of which are components of motor unit. The aim of this study was to describe the clinical, demographic, and genetic profile of children diagnosed with different NMDs.
Materials and Methods Descriptive case series study where clinical records for children with neuromuscular disorders (NMDs) how presented to the outpatient Neurology Clinic at Tripoli Children Hospital in the period from January 2015 to the date of data collection May 2023 have been reviewed to obtain the relevant information which include demographic data, parental consanguinity, family history of affected other members, diagnostic groups within NMDs used were spinal muscular atrophy (SMA) and its subtypes, Duchenne muscular dystrophy (DMD), limb girdle muscular dystrophy (LGMD) and any other NMDs, genetic testing results, ambulatory state at the time of data collection, age at death if occurred, mode of treatment (steroid for patients with diagnosis of DMD, oral Risdiplam/IV Zolgensma/intrathecal Spinraza for patients with SMA) and Genetic testing results and the eligibility to spesfic exon skipping therapy for DMD patients.
Results The study revealed 53 patients with NMDs, which represent 3.8% of all neurological disorders. Of these, 32 (60.4%) were males and 21 (39.6%) were females. Patient ages ranged between 2 months and 20 years (mean = 10 years). SMA and DMD are more common than the other disorders. 77.4% of patients were have positive consanguinity and 66% are have family history. 54.7% of patients still have ability to walk independently. Four (7.5%) patients were died three of them were have diagnosis of SMA type 1 and they died before age of 18 months and the fourth who has diagnosis of SMA type 3 was die at age of 12 years.
Conclusion Although neuromuscular disorders are rare as individual disease entities, as a group they are not. The retrospective study presented here could form the backbone of a future Libyan neuromuscular registry, which is necessary with many novel NMD therapies in pipeline.
Keywords
neuromuscular disorders - spinal muscular atrophy - Duchenne muscular dystrophy - limb girdle muscular dystrophy - novel NMD therapiesAuthors' Contribution
All the named authors contributed to the clinical care of the patients, data collection, drafting and revising of the manuscript, and approval of the final version of the article.
Compliance with Ethical Principles
This is a small case series that does not require prior ethical approval. All patients and/or their patients/guardian signed a general consent form allowing anonymous use of data for education, research, and quality improvement.
Publikationsverlauf
Artikel online veröffentlicht:
10. Oktober 2023
© 2023. The Libyan Biotechnology Research Center. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Laing NG. Genetics of neuromuscular disorders. Crit Rev Clin Lab Sci 2012; 49 (02) 33-48
- 2 Benarroch L, Bonne G, Rivier F, Hamroun D. The 2021 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord 2020; 30 (12) 1008-1048
- 3 Efthymiou S, Manole A, Houlden H. Next-generation sequencing in neuromuscular diseases. Curr Opin Neurol 2016; 29 (05) 527-536
- 4 Salih MA. ed. Muscular dystrophies and myopathies in Arab populations. In: Teebi AS. ed. Genetic Disorders among Arab Populations. 2nd ed.. Berlin: Springer-Verlag; 2010: 158-179
- 5 Jumah MA, Muhaizea MA, Rumayyan AA. et al. Current management of Duchenne muscular dystrophy in the Middle East: expert report. Neurodegener Dis Manag 2019; 9 (03) 123-133
- 6 Alassiri AH, Alyami AA, Alshabibi MI. et al. The spectrum of muscle pathologies: three decades of experience from a reference laboratory in Saudi Arabia. Ann Diagn Pathol 2020; 47: 151532
- 7 Leary R, Oyewole AO, Bushby K, Aartsma-Rus A. Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD). Neuropediatrics 2017; 48 (04) 211-220
- 8 Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis 2015; 2 (01) 73-85
- 9 Mohamed IN. Clinical profile of pediatric neurological disorders: Outpatient Department, Khartoum, Sudan. Child Neurol Open 2016; 3: 2329048 × 15623548
- 10 Esaid M. Neuromuscular Disorders in Qatar: Research Outcomes and Recommendations. Paper presented at: QScience Proceedings: Congenital Dystrophies - Neuromuscular Disorders Precision Medicine: Genomics to Care and Cure Conference; January 11–13, 2020; Doha, Qatar
- 11 Ben Halim N, Hsouna S, Lasram K. et al. Differential impact of consanguineous marriages on autosomal recessive diseases in Tunisia. Am J Hum Biol 2016; 28 (02) 171-180
- 12 Khedr EM, Fawi G, Abbas MA. et al. Prevalence of neuromuscular disorders in Qena governorate/Egypt: population-based survey. Neurol Res 2016; 38 (12) 1056-1063
- 13 Shawky R, El-Sayed NS, Ibrahim D, Seifeldin N. Profile of genetic disorders prevalent in northeast region of Cairo, Egypt. Egypt J Med Hum Genet 2012; 13: 45-62
- 14 Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008; 371 (9630): 2120-2133
- 15 Pechmann A, Kirschner J. Diagnosis and new treatment avenues in spinal muscular atrophy. Neuropediatrics 2017; 48 (04) 273-281
- 16 Finkel RS, Mercuri E, Darras BT. et al; ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1723-1732
- 17 Day J, Chiriboga C, Darras B. et al. Onasemnogene Abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): phase 3 US study (STR1VE) update (1828). Neurology 2020
- 18 De Vivo DC, Bertini E, Swoboda KJ. et al; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 2019; 29 (11) 842-856
- 19 Lowes LP, Alfano LN, Arnold WD. et al. Impact of age and motor function in a phase 1/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol 2019; 98: 39-45
- 20 Boemer F, Caberg J-H, Dideberg V. et al. Newborn screening for SMA in Southern Belgium. Neuromuscul Disord 2019; 29 (05) 343-349
- 21 Govoni A, Gagliardi D, Comi GP, Corti S. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol 2018; 55 (08) 6307-6318
- 22 Bittles A. Consanguinity and its relevance to clinical genetics. Clin Genet 2001; 60 (02) 89-98
- 23 McDonald CM, Henricson EK, Abresch RT. et al; Cinrg Investigators. The cooperative international neuromuscular research group Duchenne natural history study: a longitudinal investigation in the era of glucocorticoid therapy—design of protocol and the methods used. Muscle Nerve 2013; 48 (01) 32-54
- 24 Bushby K, Finkel R, Birnkrant DJ. et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9 (01) 77-93
- 25 Birnkrant DJ, Bushby K, Bann CM. et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018; 17 (03) 251-267
- 26 Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmüller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol 2020; 35 (07) 643-653
- 27 McDonald CM, Henricson EK, Abresch RT. et al; CINRG Investigators. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018; 391 (10119): 451-461
- 28 Moxley III RT, Ashwal S, Pandya S. et al; Quality Standards Subcommittee of the American Academy of Neurology, Practice Committee of the Child Neurology Society. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64 (01) 13-20
- 29 Ryan NJ. Ataluren: first global approval. Drugs 2014; 74 (14) 1709-1714
- 30 Mendell JR, Rodino-Klapac LR, Sahenk Z. et al; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74 (05) 637-647